60
Participants
Start Date
January 29, 2019
Primary Completion Date
March 1, 2026
Study Completion Date
March 1, 2026
Adavosertib
Given PO
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
MedStar Georgetown University Hospital, Washington D.C.
Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore
Vanderbilt Breast Center at One Hundred Oaks, Nashville
Vanderbilt University/Ingram Cancer Center, Nashville
Wayne State University/Karmanos Cancer Institute, Detroit
Weisberg Cancer Treatment Center, Farmington Hills
UC Comprehensive Cancer Center at Silver Cross, New Lenox
University of Chicago Medicine-Orland Park, Orland Park
Northwestern University, Chicago
University of Chicago Comprehensive Cancer Center, Chicago
Washington University School of Medicine, St Louis
Siteman Cancer Center-South County, St Louis
Siteman Cancer Center at Christian Hospital, St Louis
Siteman Cancer Center at West County Hospital, Creve Coeur
Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
University of Kansas Cancer Center, Kansas City
University of Kansas Clinical Research Center, Fairway
University of Kansas Hospital-Westwood Cancer Center, Westwood
M D Anderson Cancer Center, Houston
UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
UCSF Medical Center-Mount Zion, San Francisco
UCSF Medical Center-Mission Bay, San Francisco
University of California Davis Comprehensive Cancer Center, Sacramento
Massachusetts General Hospital Cancer Center, Boston
Brigham and Women's Hospital, Boston
Beth Israel Deaconess Medical Center, Boston
Dana-Farber Cancer Institute, Boston
National Cancer Institute (NCI)
NIH